Leukaemia Trial, Recruiting (NCT06891144)

Leukaemia Trial, Recruiting NCT06891144 Sponsor: French Innovative Leukemia Organisation Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06891144 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 60 years old or older
You have been newly diagnosed with a type of blood cancer called AML (acute myeloid leukemia), either developed on its own or as a result of a previous condition, and have not yet received treatment for it
Your doctors have decided that you are well enough to receive standard intensive treatment
You have read the information provided about the trial and have agreed to have your data collected by signing a consent form

Who may not be able to join:

You have a specific subtype of AML known as AML3 (also called acute promyelocytic leukemia)
You have a serious infection that is not under control at the time of joining the trial
You have mental health or personal/social circumstances that would make it difficult to follow the trial's requirements
You do not have health insurance or are not registered with a social security scheme

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06891144

Sponsor: French Innovative Leukemia Organisation

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

More information: https://clinicaltrials.gov/study/NCT06891144

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 60 years old or older
You have been newly diagnosed with a type of blood cancer called AML (acute myeloid leukemia), either developed on its own or as a result of a previous condition, and have not yet received treatment for it
Your doctors have decided that you are well enough to receive standard intensive treatment
You have read the information provided about the trial and have agreed to have your data collected by signing a consent form

Who may not be able to join:

You have a specific subtype of AML known as AML3 (also called acute promyelocytic leukemia)
You have a serious infection that is not under control at the time of joining the trial
You have mental health or personal/social circumstances that would make it difficult to follow the trial's requirements
You do not have health insurance or are not registered with a social security scheme

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

French Innovative Leukemia Organisation

Registry

ClinicalTrials.gov

Start date

6 January 2015

Est. completion

6 January 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older; describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older; Describe first line AML treatment received; characterize the Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov